MedTrace Logo

P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid

NCT02946710 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2018-04-03

No results posted yet for this study

Summary

This research will be achieved by the assessment of p75NTR-ECD expression (total and linked to different species of Aβ (Aβ1-40 and Aβ-1-42)) within the cerebrospinal fluid (CSF) of patients with AD dementia, mild cognitive impairment (MCI) due to AD, frontotemporal dementia and non-neurodegenerative dementia.

Conditions

  • Alzheimer Disease

Interventions

BIOLOGICAL

cerebrospinal fluid

Biological analysis on cerebrospinal fluid

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Delisle Marie-Bernadette, MD · University Hospital, Toulouse

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-06-30
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02946710 on ClinicalTrials.gov